ChemoCentryx, Inc. (CCXI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 27.51 |
| Open | 27.77 |
| Bid | 25.00 x 2900 |
| Ask | 26.15 x 800 |
| Day's Range | 25.14 - 27.79 |
| 52 Week Range | 12.71 - 42.16 |
| Volume | |
| Avg. Volume | 1,470,450 |
| Market Cap | 1.862B |
| Beta (5Y Monthly) | 1.94 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.01 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 76.57 |
- Zacks
Catalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
The five-year returns have been stellar for ChemoCentryx (NASDAQ:CCXI) shareholders despite underlying losses increasing
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...
- GlobeNewswire
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of safety results from the ongoing Phase I clinical study of CCX559, the Company’s highly potent, orally administered PD-L1 checkpoint
© 2022 Yahoo. All rights reserved.
